COVID-19 rapid guideline: managing COVID-19 (NG191)Product type:GuidanceProgramme:NICE guidelineLast updated: 8 May 2024Published: 23 March 2021
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 May 2024
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 13 March 2024Published: 29 March 2023
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)Product type:GuidanceProgramme:NICE guidelineLast updated: 25 January 2024Published: 18 December 2020
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)Product type:GuidanceProgramme:NICE guidelineLast updated: 28 September 2023Published: 1 April 2020
Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 June 2023
RespiraSense for continuously monitoring respiratory rate (MIB299)Product type:AdviceProgramme:Medtech innovation briefingPublished: 5 July 2022
SYNE-COV for predicting COVID-19 outcomes (MIB264)Product type:AdviceProgramme:Medtech innovation briefingPublished: 15 June 2021
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)Product type:AdviceProgramme:Medtech innovation briefingPublished: 26 August 2020
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)Product type:AdviceProgramme:Medtech innovation briefingPublished: 10 July 2020
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)Product type:AdviceProgramme:Medtech innovation briefingPublished: 21 May 2020
Lifelight First for monitoring vital signs (MIB213)Product type:AdviceProgramme:Medtech innovation briefingPublished: 8 April 2020